Global Preimplantation Genetic Screening (PGS) Technology Market – Industry Trends and Forecast to 2029

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

Global Preimplantation Genetic Screening (PGS) Technology Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Aug 2022
  • Global
  • 350 页面
  • 桌子數: 220
  • 图号: 60

Global Preimplantation Genetic Screening Pgs Technology Market

市场规模(十亿美元)

CAGR :  % Diagram

Chart Image USD 552.50 Million USD 1,228.09 Million 2021 2029
Diagram Forecast Period
2022 –2029
Diagram Market Size (Base Year)
USD 552.50 Million
Diagram Market Size (Forecast Year)
USD 1,228.09 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>Global Preimplantation Genetic Screening (PGS) Technology Market, By Procedure Type (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis), Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence in Situ Hybridization, Comparative Genomic Hybridization, Single-Nucleotide Polymorphism), Product and Services (Reagents and Consumables, Instruments, Software and Services), End User (Maternity Centers and Fertility Clinics, Hospitals, Diagnostic Labs, and Service Providers, Research Laboratories and Academic Institutes), Test Type (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, HLA Typing, Other PGT Types), Application (Embryo HLA Typing for Stem Cell Therapy, IVF Prognosis, Late Onset Genetic Disorders, Inherited Genetic Disease, Others) – Industry Trends and Forecast to 2029

Preimplantation Genetic Screening (PGS) Technology Market

Preimplantation Genetic Screening (PGS) Technology Market Analysis and Size

The size of the global market for preimplantation genetic screening (PGS) technology is anticipated to grow at a CAGR of 10.50% during the forecast period. Recent technological developments have significantly altered the practice of prenatal screening and early diagnosis of chromosomal abnormalities in an embryo. Successful in vitro fertilisation (IVF) processing has been achieved by expanding non-invasive cell-free foetal DNA-based detection procedures as well as carrier screening panels into prenatal care. Preimplantation genetic screening (PGS) technology is a market-driver due to the early detection of congenital disorders in the beginning phases of the IVF workflow, gradually reducing the chance of inherited chromosomal abnormalities in foetuses.

Data Bridge Market Research analyses that the preimplantation genetic screening (PGS) technology market which was USD 552.50 million in 2021, would rocket up to USD 1228.09 million by 2029, and is expected to undergo a CAGR of 10.50% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Preimplantation Genetic Screening (PGS) Technology Market Scope and Segmentation      

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Procedure Type (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis), Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence in Situ Hybridization, Comparative Genomic Hybridization, Single-Nucleotide Polymorphism), Product and Services (Reagents and Consumables, Instruments, Software and Services), End User (Maternity Centers and Fertility Clinics, Hospitals, Diagnostic Labs, and Service Providers, Research Laboratories and Academic Institutes), Test Type (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, HLA Typing, Other PGT Types), Application (Embryo HLA Typing for Stem Cell Therapy, IVF Prognosis, Late Onset Genetic Disorders, Inherited Genetic Disease, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Beijing Genomics Institute (BGI) (China), Abbott (U.S.), Siemens (Germany), QIAGEN (Germany)

Market Opportunities

  • Rising number of fertility clinics around the world
  • Prevalence of funds from government and private organisations for preimplantation genetic screening

Market Definition

Preimplantation genetic screening (PGS), also known as PGTa (preimplantation testing for aneuploidy), is a specialised, cutting-edge diagnostic procedure used to ascertain the chromosomal status of embryos at a very early stage of embryo development. It is an additional or "add-on" to standard IVF/ICSI therapy.

Preimplantation Genetic Screening (PGS) Technology Market Dynamics

Drivers

  • Rising number of fertility clinics

In the forecast period of 2022–2029, factors such as the rising number of fertility clinics around the world, the prevalence of funds from government and private organisations for preimplantation genetic screening, the declining rate of fertility, the adoption of cutting-edge technology, and the rising risk of chromosomal abnormalities with increasing maternal age are likely to boost the growth of the preimplantation genetic screening (PGS) technology market.

  • Increase in healthcare infrastructure

The preimplantation genetic screening (PGS) technology market will expand throughout the forecast period due to the prevalence of an enhanced healthcare infrastructure and an increase in tourist activities.

Opportunities

The growth of the preimplantation genetic screening (PGS) technology market is fuelled by the prevalence of funds from government and private organisations for preimplantation genetic screening, the declining fertility rate, and the adoption of cutting-edge technology. This will provide beneficial opportunities for the market growth.

Restraints/Challenges

  • High cost

On the other hand, the stringent government regulations and the high procedure cost will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the preimplantation genetic screening (PGS) technology market.

This preimplantation genetic screening (PGS) technology market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the preimplantation genetic screening (PGS) technology market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Preimplantation Genetic Screening (PGS) Technology Market Scope

The preimplantation genetic screening (PGS) technology market is segmented on the basis of procedure type, technology, product & services, test type, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Procedure Type

  • Preimplantation Genetic Screening
  • Preimplantation Genetic Diagnosis

 Technology

  • Next-Generation Sequencing
  • Polymerase Chain Reaction
  • Fluorescence in Situ Hybridization
  • Comparative Genomic Hybridization
  • Single-Nucleotide Polymorphism

 Product and Services

  • Reagents and Consumables
  • Instruments
  • Software and Services

End User

  • Maternity Centers
  • Fertility Clinics
  • Hospitals, Diagnostic Labs
  • Service Providers
  • Research Laboratories
  • Academic Institutes

 Test Type

  • Chromosomal Abnormalities
  • X-linked Diseases, Embryo Testing
  • Aneuploidy Screening
  • HLA Typing
  • Other PGT Types

 Application

  • Embryo HLA Typing for Stem Cell Therapy
  • IVF Prognosis
  • Late Onset Genetic Disorders
  • Inherited Genetic Disease
  • Others

Preimplantation Genetic Screening (PGS) Technology Market Regional Analysis/Insights

The preimplantation genetic screening (PGS) technology market is analysed and market size insights and trends are provided by country, procedure type, technology, product & services, test type, application and end user as referenced above.

The countries covered in the preimplantation genetic screening (PGS) technology market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the preimplantation genetic screening (PGS) technology market due to the growing number of late pregnancies along with rising adoption of IVF procedures.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the growing number of advancements and adoption of PGT workflows.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Preimplantation Genetic Screening (PGS) Technology Market Share Analysis

The preimplantation genetic screening (PGS) technology market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to preimplantation genetic screening (PGS) technology market.

Some of the major players operating in the preimplantation genetic screening (PGS) technology market are:

  • Illumina, Inc. (U.S.)
  • Thermo Fisher Scientific Inc. (U.S.)
  • Agilent Technologies, Inc. (U.S.)
  • PerkinElmer, Inc. (U.S.)
  • CooperSurgical, Inc. (U.S.)
  • Beijing Genomics Institute (BGI) (China)
  • Abbott (U.S.)
  • Siemens (Germany)
  • QIAGEN (Germany)

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外,市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息,请请求分析师致电或下拉您的询问。

DBMR 研究团队使用的关键研究方法是数据三角测量,其中包括数据挖掘、数据变量对市场影响的分析和主要(行业专家)验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息,请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制,包括目标品牌的价格趋势分析、了解其他国家的市场(索取国家列表)、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表(事实手册)中的数据,或者可以帮助您根据报告中的数据集创建演示文稿。

Frequently Asked Questions

市场是基于 Global Preimplantation Genetic Screening (PGS) Technology Market, By Procedure Type (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis), Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence in Situ Hybridization, Comparative Genomic Hybridization, Single-Nucleotide Polymorphism), Product and Services (Reagents and Consumables, Instruments, Software and Services), End User (Maternity Centers and Fertility Clinics, Hospitals, Diagnostic Labs, and Service Providers, Research Laboratories and Academic Institutes), Test Type (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, HLA Typing, Other PGT Types), Application (Embryo HLA Typing for Stem Cell Therapy, IVF Prognosis, Late Onset Genetic Disorders, Inherited Genetic Disease, Others) – Industry Trends and Forecast to 2029 进行细分的。
在2021年,Global Preimplantation Genetic Screening (PGS) Technology Market的规模估计为552.50 USD Million美元。
Global Preimplantation Genetic Screening (PGS) Technology Market预计将在2022年至2029年的预测期内以CAGR 10.5%的速度增长。
该市场报告涵盖U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.的数据。
Testimonial